Evidence review

SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review

What's breaking down if you have Diabetic neuropathy

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why SS-31 (Elamipretide) might help you

You are reading about Diabetic neuropathy — what breaks down matters before any compound name.
Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

SS-31 (Elamipretide) → mitochondrial

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 5
Claims tagged human evidence: 2
Claims tagged preclinical (animal/lab): 1
Claims tagged anecdotal: 0
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 5

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.41 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Elamipretide: A Review of Its Structure, Mechanism of Action, and Clinical Applications (source s1)

Details cardiolipin binding and ROS reduction mechanism.

Evidence type: Published research.

PubMed.gov

Study

Elamipretide: A Review of Its Structure, Mechanism of Action, and Clinical Applications

Details cardiolipin binding and ROS reduction mechanism.

2026-06-29 23:56s1 · #5834869991c1

Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy (source s2)

Mouse diabetic nephropathy study with functional and histological improvements.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

PubMed.gov

Study

Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy

Mouse diabetic nephropathy study with functional and histological improvements.

2026-06-29 23:56s2 · #d975e06a21db

SS-31 for diabetic nephropathy (source s3)

Systematic review notes lack of human confirmation even for kidney.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

SS-31 for diabetic nephropathy

Systematic review notes lack of human confirmation even for kidney.

2026-06-29 23:56s3 · #a5d06b40b312

The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes (source s4)

Human cell data on ROS reduction.

Evidence type: Published research.

PubMed.gov

Study

The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes

Human cell data on ROS reduction.

2026-06-29 23:56s4 · #035bf4d85e05

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy (source s5)

Phase 3 trial results.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy

Phase 3 trial results.

2026-06-29 23:56s5 · #4c920711a3c3

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 5 sources · swipe →chain 4c920711a3c3 · verify chain · provenance

1 / 5

PubMed.gov

Study

Elamipretide: A Review of Its Structure, Mechanism of Action, and Clinical Applications

Details cardiolipin binding and ROS reduction mechanism.

2026-06-29 23:56s1 · #5834869991c1

PubMed.gov

Study

Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy

Mouse diabetic nephropathy study with functional and histological improvements.

2026-06-29 23:56s2 · #d975e06a21db

PubMed.gov

Study

SS-31 for diabetic nephropathy

Systematic review notes lack of human confirmation even for kidney.

2026-06-29 23:56s3 · #a5d06b40b312

PubMed.gov

Study

The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes

Human cell data on ROS reduction.

2026-06-29 23:56s4 · #035bf4d85e05

PubMed.gov

Study

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy

Phase 3 trial results.

2026-06-29 23:56s5 · #4c920711a3c3

Evidence ledger 5 · tier-ranked · API

humanlow confidence

No published human clinical trials test SS-31 for diabetic neuropathy.

sources: s3

humanlow confidence

Phase 3 trial of SS-31 in primary mitochondrial myopathy failed primary endpoints.

sources: s5

preclinicallow confidence

In diabetic mouse models SS-31 reduced proteinuria and glomerular damage via lower renal mitochondrial ROS.

sources: s2

mechanisticlow confidence

SS-31 binds cardiolipin and reduces mitochondrial ROS in stressed cells.

sources: s1

mechanisticlow confidence

Ex vivo treatment of leukocytes from type 2 diabetes patients with SS-31 lowered mitochondrial ROS.

sources: s4

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-29 23:56

SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review · 5 claims · 5 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Diabetic Neuropathy
Slug: ss-31-diabetic-neuropathy
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"Diabetic neuropathy","condition_key":"diabetic-neuropathy","primary_peptide":"ss-31","peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section

it output

{
  "slug": "ss-31-diabetic-neuropathy",
  "title": "SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review",
  "body": "## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve damage linked to chronic high blood sugar. Mitochondrial dysfunction sits at the core. Hyperglycemia drives excess reactive oxygen species inside nerve cell mitochondria. This damages cardiolipin in the inner membrane, impairs electron transport, lowers ATP output, and triggers further oxidative stress plus inflammation. Over time, axons degenerate, Schwann cells suffer, and sensory, motor, or autonomic nerves lose function. The process is degenerative: breakdown outruns repair in mitochondria-rich nerve tissue. No approved peptide reverses this; management focuses on glucose control and symptom relief.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial oxidative damage in nerves is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 binds cardiolipin on the inner mitochondrial membrane. In damaged mitochondria it scavenges ROS, stabilizes membrane structure, reduces electron leak, and supports ATP production. Preclinical dia

f861a16d62f7a2ea

Machine verification: /api/articles/ss-31-diabetic-neuropathy/contributions

Ask this article · 7 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human clinical trials test SS-31 for diabetic neuropathy."?

ask ss-31-diabetic-neuropathy claim c3 · paste includes §SELF

What does the ledger say about this (human tier): "Phase 3 trial of SS-31 in primary mitochondrial myopathy failed primary endpoints."?

ask ss-31-diabetic-neuropathy claim c5 · paste includes §SELF

What does the ledger say about this (preclinical tier): "In diabetic mouse models SS-31 reduced proteinuria and glomerular damage via lower renal mitochondrial ROS."?

ask ss-31-diabetic-neuropathy claim c2 · paste includes §SELF

What does the ledger say about this (mechanistic tier): "SS-31 binds cardiolipin and reduces mitochondrial ROS in stressed cells."?

ask ss-31-diabetic-neuropathy claim c1 · paste includes §SELF

What does the ledger say about this (mechanistic tier): "Ex vivo treatment of leukocytes from type 2 diabetes patients with SS-31 lowered mitochondrial ROS."?

ask ss-31-diabetic-neuropathy claim c4 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review — and what would you need me to tell you first?

ask ss-31-diabetic-neuropathy condition gaps · paste includes §SELF

What good and bad outcomes are documented for SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review (studies vs anecdotes)?

ask ss-31-diabetic-neuropathy good bad experiences · paste includes §SELF

What's breaking down if you have Diabetic neuropathy

Why SS-31 (Elamipretide) might help you

How these fit together

What the evidence actually shows

What scientists say

Elamipretide: A Review of Its Structure, Mechanism of Action, and Clinical Applications (source s1)

Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy (source s2)

SS-31 for diabetic nephropathy (source s3)

The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes (source s4)

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy (source s5)

Connected articles

Related articles